The present invention provides compounds (n-3 PUFA derivatives) of formula (I): ##STR00001##
that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

The present invention provides compounds (n-3 PUFA derivatives) of formula (I): ##STR00001##
that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.

The invention provides novel compounds of formula (I) and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. In formula (I), X is O, NR (where R is either H or C.sub.1-3 alkyl, e.g. CH.sub.3), or CH.sub.2; R.sup.3 is H, F, CI, Br, I, or CH.sub.3; R.sup.4 is H, or OH; R.sup.5 and R.sup.6 are independently selected from H and OH, or R.sup.5 and R.sup.6 together are ?O; R.sup.7 is H, F, CI, Br, I, or CH.sub.3; R.sup.8 is H, OH, or OC(O)NR.sub.2 (where each R is independently H or C.sub.1-3 alkyl, e.g. CH.sub.3), preferably R.sup.8 is H, OH or OC(O)NH.sub.2; R.sup.9 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R.sup.9 is an optionally substituted straight-chained or branched C.sub.1-6 alkyl group (e.g. C.sub.1-3 alkyl group); R.sup.10 is a straight-chained or branched C.sub.1-8 alkyl group (e.g. C.sub.1-6 alkyl group), a C.sub.4-6 cycloalkyl group, or an optionally substituted aryl or heteroaryl group; and each --- independently represents an optional bond (i.e. each of C.sub.2-C.sub.3, C.sub.4-C.sub.5, C.sub.6-C.sub.7, C.sub.8-C.sub.9, C.sub.10-C.sub.11 and C.sub.18-C.sub.19 are independently either CC (single) or C?C (double) bonds).

##STR00001##

The invention provides novel compounds of formula (I) and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. In formula (I), X is O, NR (where R is either H or C.sub.1-3 alkyl, e.g. CH.sub.3), or CH.sub.2; R.sup.3 is H, F, CI, Br, I, or CH.sub.3; R.sup.4 is H, or OH; R.sup.5 and R.sup.6 are independently selected from H and OH, or R.sup.5 and R.sup.6 together are ?O; R.sup.7 is H, F, CI, Br, I, or CH.sub.3; R.sup.8 is H, OH, or OC(O)NR.sub.2 (where each R is independently H or C.sub.1-3 alkyl, e.g. CH.sub.3), preferably R.sup.8 is H, OH or OC(O)NH.sub.2; R.sup.9 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R.sup.9 is an optionally substituted straight-chained or branched C.sub.1-6 alkyl group (e.g. C.sub.1-3 alkyl group); R.sup.10 is a straight-chained or branched C.sub.1-8 alkyl group (e.g. C.sub.1-6 alkyl group), a C.sub.4-6 cycloalkyl group, or an optionally substituted aryl or heteroaryl group; and each --- independently represents an optional bond (i.e. each of C.sub.2-C.sub.3, C.sub.4-C.sub.5, C.sub.6-C.sub.7, C.sub.8-C.sub.9, C.sub.10-C.sub.11 and C.sub.18-C.sub.19 are independently either CC (single) or C?C (double) bonds).

##STR00001##

A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (CNS) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.

A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (CNS) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.

The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogs, their preparation, isolation, identification, purification and uses thereof.

A first tire member manufacturing method includes an operation in which a master batch is made, and an operation in which the master batch, peptizing agent, and processing additive are mixed. The operation in which the master batch is made includes an operation in which carbon-black-containing pre-coagulation rubber latex is coagulated to obtain a coagulum, an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum, and an operation in which the compound according to Formula (I) is dispersed within the coagulum. ##STR00001## In Formula (I), R.sup.1 and R.sup.2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons. R.sup.1 and R.sup.2 may be the same or different. M.sup.+ indicates sodium ion, potassium ion, or lithium ion.

A first tire member manufacturing method includes an operation in which a master batch is made, and an operation in which the master batch, peptizing agent, and processing additive are mixed. The operation in which the master batch is made includes an operation in which carbon-black-containing pre-coagulation rubber latex is coagulated to obtain a coagulum, an operation in which a compound according to Formula (I), below, is added to the water-containing coagulum, and an operation in which the compound according to Formula (I) is dispersed within the coagulum. ##STR00001## In Formula (I), R.sup.1 and R.sup.2 each indicates a hydrogen atom, an alkyl group having 1 to 20 carbons, an alkenyl group having 1 to 20 carbons, or an alkynyl group having 1 to 20 carbons. R.sup.1 and R.sup.2 may be the same or different. M.sup.+ indicates sodium ion, potassium ion, or lithium ion.